Report of Foreign Issuer (6-k)
July 05 2013 - 6:22AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF
1934
For the month of July, 2013
Commission File Number
Novogen Limited
(Translation of registrants name into English)
16-20
Edgeworth David Ave, Hornsby, NSW 2077, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
x
Form 40-F
¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
¨
Note
: Regulation S-T Rule 101(b)(1) only permits the submission in paper
of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
¨
Note
: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and
make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrants home country), or under the rules of the home country exchange on which the registrants
securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrants security holders, and, if discussing a material event, has already been the subject of
a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark if the registrant by furnishing the
information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934. Yes
¨
No
x
If yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Novogen Limited
(Registrant)
|
|
Andrew Bursill
|
|
Andrew Bursill
|
Company Secretary
|
|
Date 5 July 2013
|
Appendix 3B
New issue announcement
Rule 2.7, 3.10.3, 3.10.4, 3.10.5
Appendix 3B
New issue announcement,
application for quotation of additional
securities
and agreement
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASXs property and may be made public.
Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.
|
Name of entity
|
Novogen Limited (Novogen)
|
We (the entity) give ASX the following information.
Part 1 - All issues
You must complete the relevant sections (attach sheets if there is
not enough space).
|
|
|
|
|
|
|
|
|
1
|
|
+
Class of
+
securities issued or to be issued
|
|
|
|
|
|
Convertible note (unquoted) (
Note
)
|
|
|
|
|
|
|
|
|
Option to acquire 1 fully-paid ordinary share (unquoted) (
Option
)
|
|
|
|
|
|
|
|
|
|
2
|
|
Number of
+
securities issued or to be issued (if known) or maximum number which may be issued
|
|
|
|
Securities not to be
quoted
:
|
|
|
|
|
|
|
|
Note with a face value of $1,100,000 on issue
|
|
|
|
|
|
|
|
4,000,000 Options
|
+
|
See chapter 19 for defined terms.
|
24/10/2005
Appendix 3B Page 1
Appendix 3B
New issue announcement
|
|
|
|
|
|
|
|
|
|
|
|
|
3
|
|
Principal terms of the
+
securities (eg, if options, exercise price and expiry date; if partly paid
+
securities, the amount outstanding and due dates for
payment; if
+
convertible securities, the conversion price
and dates for conversion)
|
|
|
|
Note
|
|
|
|
|
|
|
Face value
: $1,100,000.
|
|
|
|
|
|
|
The Note does not bear interest and is unsecured.
|
|
|
|
|
|
|
Conversion
:
|
|
|
|
|
|
|
|
|
|
|
Right of Hudson Bay Master Fund Ltd (HBMF):
HMBF may convert all or part of the face value of the Note at any time between 21 days and 24 months
after its date of issue, provided that the amount converted in each tranche is:
|
|
|
|
|
|
|
|
|
|
|
|
|
no less
than $25,000 (except the last tranche); and
|
|
|
|
|
|
|
|
|
|
|
|
|
no more
than 50% of the face value of the most recently issued Note at that time (unless the number of Shares to be issued on conversion will not exceed the volume of Shares traded on ASX in the immediately preceding week);
|
|
|
|
|
|
|
|
|
|
|
Right of Novogen:
Novogen may require HMBF to convert all (but not part) of the total amount unpaid on the Note if the daily VWAP per Share exceeds
$0.28 for 20 consecutive trading days;
|
|
|
|
|
|
|
|
|
|
|
Conversion price
: at the election of HBMF
|
|
|
|
|
|
|
|
|
|
|
|
|
90% of
the average daily VWAP per Share on ASX on any 3 days during the 20 trading days immediately prior to the date of conversion; or
|
|
|
|
|
|
|
|
|
|
|
|
|
130% of
the average daily VWAP per Share on ASX during the 20 trading days immediately prior to 3 July 2013 but only up to $450,000 of the face value of the Note
|
|
|
|
|
|
|
|
|
|
|
Shares issued upon conversion of the Note will rank pari passu with all existing Shares
|
|
|
|
|
|
|
Options
|
|
|
|
|
|
|
|
|
Exercise price per Option
: 130% of the average daily VWAP per Share traded on ASX for the 20 trading days immediately prior to 3 July
2013
|
|
|
|
|
|
|
|
|
Exercise period
: on or before 5 July 2016
|
+
|
See chapter 19 for defined terms.
|
|
|
|
Appendix 3B Page 2
|
|
24/10/2005
|
Appendix 3B
New issue announcement
|
|
|
|
|
|
|
|
|
|
|
4
|
|
Do the
+
securities rank equally in all respects from the date of allotment with an existing
+
class of quoted
+
securities?
If the additional securities do not rank equally, please state:
|
|
|
|
Neither the Note nor any of the Options referred to in Item 2 will rank
equally with any existing class of quoted securities of Novogen.
|
|
|
|
|
|
In addition:
|
|
|
|
|
the date from which they do
|
|
|
|
|
|
the Note will not entitle its holder to participate in any dividends declared or paid by Novogen;
|
|
|
|
|
the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
the Note will not entitle its holder to any interest payment, except upon the occurrence of an Event of
Default under the Agreement, in which case interest will accrue at the rate prescribed under section 101 of the
Civil Procedure Act 2005
(NSW) until the Event of Default has been remedied; and
|
|
|
|
|
the extent to which they do not rank equally, other
than in relation to the next dividend, distribution or interest payment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
none of the Options referred to in Item 2 will entitle its holder to participate in any dividends declared or paid by Novogen or any interest payments.
|
|
|
|
|
|
|
|
|
|
|
|
5
|
|
Issue price or consideration
|
|
|
|
|
|
Issue price per Note: $1,000,000 (Face Value $1,100,000)
|
|
|
|
|
|
|
|
|
|
|
Issue price for Options: no additional cash consideration
|
|
|
|
|
|
|
|
|
|
|
|
6
|
|
Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)
|
|
|
|
The
Note and free-attaching Options referred to in Item 2 are issued in consideration for the investment by HBMF of $1,000,000 into Novogen, details of which were announced to the market on or about 4 July 2012.
The purpose of the Note is to secure funds for general corporate and working capital
purposes.
|
|
|
|
|
|
|
|
|
|
6a
|
|
Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?
|
|
|
|
No
|
|
|
If Yes, complete sections 6b 6h in relation
to the +securities the subject of this Appendix 3B, and comply with section 6i
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6b
|
|
The date the security holder resolution under rule 7.1A was passed
|
|
|
|
N/A
|
+
|
See chapter 19 for defined terms.
|
|
|
|
24/10/2005 Appendix 3B Page 3
|
|
|
Appendix 3B
New issue announcement
|
|
|
|
|
|
|
|
|
|
|
6c
|
|
Number of +securities issued without security holder approval under rule 7.1
|
|
|
|
N/A
|
|
|
|
|
|
|
|
|
|
|
|
6d
|
|
Number of +securities issued with security holder approval under rule 7.1A
|
|
|
|
N/A
|
|
|
|
|
|
|
|
|
|
|
|
6e
|
|
Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
|
|
|
|
N/A
|
|
|
|
|
|
|
|
|
|
|
|
6f
|
|
Number of +securities issued under an exception in rule 7.2
|
|
|
|
N/A
|
|
|
|
|
|
|
|
|
|
|
|
6g
|
|
If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the
source of the VWAP calculation.
|
|
|
|
N/A
|
|
|
|
|
|
|
|
|
|
|
|
6h
|
|
If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market
Announcements
|
|
|
|
N/A
|
|
|
|
|
|
|
|
|
|
|
|
6I
|
|
Calculate the entitys remaining issue capacity under rule 7.1 and rule 7.1A complete Annexure 1 and release to ASX Market Announcements
|
|
|
|
N/A
|
+
|
See chapter 19 for defined terms.
|
|
|
|
Appendix 3B Page 4
|
|
1/1/2003
|
Appendix 3B
New issue announcement
|
|
|
|
|
|
|
|
|
|
|
7
|
|
+Issue dates
Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata
entitlement issue must comply with the applicable timetable in Appendix 7A.
Cross reference: item 33 of Appendix 3B.
|
|
|
|
8 July 2013 for the Options and the
Note
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number
|
|
+
Class
|
8
|
|
Number and
+
class of all
+
securities quoted on ASX (
including
the securities
in clause 2 if applicable)
|
|
|
|
139,098,402
|
|
Shares
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number
|
|
+
Class
|
9
|
|
Number and
+
class of all
+
securities not quoted on ASX (
including
the
securities in clause 2 if applicable)
|
|
|
|
1
|
|
Note with a face value of $1,100,000 on issue
|
|
|
|
|
|
|
|
|
60,000,000
|
|
Unquoted
convertible note, with aggregate face values of $1,500,000
|
|
|
|
|
|
|
|
|
6,007,216
|
|
Options, each to acquire 1 Share, exercisable at various exercise prices and by various expiry dates
|
|
|
|
|
|
|
|
|
|
|
|
10
|
|
Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)
|
|
|
|
N/A
|
Part 2 - Bonus issue or pro rata
issue
|
|
|
|
|
|
|
11
|
|
Is security holder approval required?
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12
|
|
Is the issue renounceable or non-renounceable?
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13
|
|
Ratio in which the +securities will be offered
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14
|
|
+
Class of
+
securities to which the offer relates
|
|
|
|
|
+
|
See chapter 19 for defined terms.
|
|
|
|
24/10/2005 Appendix 3B Page 5
|
|
|
Appendix 3B
New issue announcement
|
|
|
|
|
|
|
15
|
|
+
Record date to determine entitlements
|
|
|
|
|
|
|
|
|
|
|
|
16
|
|
Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
|
|
|
|
|
|
|
|
|
|
|
|
17
|
|
Policy for deciding entitlements in relation to fractions
|
|
|
|
|
|
|
|
|
|
|
|
18
|
|
Names of countries in which the entity has
+
security holders who will not be sent new issue documents
Note: Security holders must be told how their entitlements are to be dealt
with.
Cross reference: rule 7.7.
|
|
|
|
|
|
|
|
|
|
|
|
19
|
|
Closing date for receipt of acceptances or renunciations
|
|
|
|
|
|
|
|
|
|
|
|
20
|
|
Names of any underwriters
|
|
|
|
|
|
|
|
|
|
|
|
21
|
|
Amount of any underwriting fee or commission
|
|
|
|
|
|
|
|
|
|
|
|
22
|
|
Names of any brokers to the issue
|
|
|
|
|
|
|
|
|
|
|
|
23
|
|
Fee or commission payable to the broker to the issue
|
|
|
|
|
|
|
|
|
|
|
|
24
|
|
Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of
+
security holders
|
|
|
|
|
|
|
|
|
|
|
|
25
|
|
If the issue is contingent on
+
security holders approval, the date of the meeting
|
|
|
|
|
|
|
|
|
|
|
|
26
|
|
Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled
|
|
|
|
|
+
|
See chapter 19 for defined terms.
|
|
|
|
Appendix 3B Page 6
|
|
1/1/2003
|
Appendix 3B
New issue announcement
|
|
|
|
|
|
|
|
|
|
|
27
|
|
If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
|
|
|
|
|
|
|
|
|
|
|
|
28
|
|
Date rights trading will begin (if applicable)
|
|
|
|
|
|
|
|
|
|
|
|
29
|
|
Date rights trading will end (if applicable)
|
|
|
|
|
|
|
|
|
|
|
|
30
|
|
How do
+
security holders sell their entitlements
in full
through a broker?
|
|
|
|
|
|
|
|
|
|
|
|
31
|
|
How do
+
security holders sell
part
of their entitlements through a broker and accept for the balance?
|
|
|
|
|
|
|
|
|
|
|
|
32
|
|
How do
+
security holders dispose of their entitlements (except by sale through a broker)?
|
|
|
|
|
|
|
|
|
|
|
|
33
|
|
+
Despatch date
|
|
|
|
|
|
|
|
Part 3 - Quotation of securities
|
|
|
|
|
You need only complete this section if you are
applying for quotation of securities
|
|
|
|
|
|
|
|
|
|
|
|
34
|
|
Type of securities
(
tick one
)
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
|
x
|
|
Securities described in Part 1
|
|
|
|
|
|
|
|
|
|
|
|
|
(b)
|
|
¨
|
|
All other securities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction
ends, securities issued on expiry or conversion of convertible securities
|
Entities that have ticked box 34(a)
Additional securities forming a new class of securities
Tick to indicate you are
providing the information or documents
+
|
See chapter 19 for defined terms.
|
|
|
|
24/10/2005 Appendix 3B Page 7
|
|
|
Appendix 3B
New issue announcement
|
|
|
|
|
|
|
|
|
|
|
35
|
|
¨
|
|
If the
+
securities are
+
equity securities, the names of the 20 largest holders of
the additional
+
securities, and the number and percentage
of additional
+
securities held by those
holders
|
|
|
|
36
|
|
¨
|
|
If the
+
securities are
+
equity securities, a distribution schedule of the
additional
+
securities setting out the number of holders
in the categories
|
|
|
|
|
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and
over
|
|
|
|
37
|
|
¨
|
|
A copy of any trust deed for the additional
+
securities
|
|
|
|
|
|
|
|
|
|
Entities that have ticked box 34(b)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
38
|
|
Number of securities for which
+
quotation is sought
|
|
|
|
|
|
|
|
|
|
|
|
39
|
|
Class of
+
securities for which quotation is sought
|
|
|
|
|
|
|
|
|
|
|
|
40
|
|
Do the
+
securities rank equally in all respects from the date of allotment with an existing
+
class of quoted
+
securities?
If the additional securities do not rank equally, please state:
|
|
|
|
|
|
|
|
|
the date from which they do
|
|
|
|
|
|
|
|
|
the extent to which they participate for the next dividend, (in the
case of a trust, distribution) or interest payment
|
|
|
|
|
|
|
|
|
the extent to which they do not rank equally, other than in
relation to the next dividend, distribution or interest payment
|
|
|
|
|
|
|
|
|
|
|
|
41
|
|
Reason for request for quotation now
Example: In the case of restricted securities, end of restriction period
(if issued upon conversion of another security, clearly identify that other security)
|
|
|
|
|
+
|
See chapter 19 for defined terms.
|
|
|
|
Appendix 3B Page 8
|
|
1/1/2003
|
Appendix 3B
New issue announcement
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number
|
|
+
Class
|
42
|
|
Number and
+
class of all
+
securities quoted on ASX (
including
the securities
in clause 38)
|
|
|
|
|
|
|
+
|
See chapter 19 for defined terms.
|
|
|
|
24/10/2005 Appendix 3B Page 9
|
|
|
Appendix 3B
New issue announcement
Quotation agreement
1
|
+
Quotation of our additional
+
securities is in ASXs absolute discretion. ASX may quote the
+
securities on any conditions it decides.
|
2
|
We warrant the following to ASX.
|
|
|
|
The issue of the
+
securities to be quoted complies with the law and is not
for an illegal purpose.
|
|
|
|
There is no reason why those
+
securities should not be granted
+
quotation.
|
|
|
|
An offer of the
+
securities for sale within 12 months after their issue
will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.
|
Note: An
entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
|
|
|
Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any
+
securities to be quoted and that no-one has any right to return any
+
securities to be quoted under sections 737, 738 or 1016F
of the Corporations Act at the time that we request that the
+
securities be quoted.
|
|
|
|
If we are a trust, we warrant that no person has the right to return the
+
securities to be quoted under section 1019B of the Corporations Act at the time that we request that the
+
securities be quoted.
|
3
|
We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in
this agreement.
|
4
|
We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before
+
quotation of the
+
securities begins. We acknowledge that ASX is relying on the
information and documents. We warrant that they are (will be) true and complete.
|
|
|
|
|
|
|
|
|
|
Sign here:
|
|
|
|
Date:
|
|
5 July 2013
|
|
|
|
|
(Company secretary)
|
|
|
|
|
|
|
|
|
|
|
|
Print name:
|
|
Andrew Bursill
|
|
|
|
|
|
|
+
|
See chapter 19 for defined terms.
|
|
|
|
Appendix 3B Page 10
|
|
1/1/2003
|
Appendix 3B
New issue announcement
Appendix 3B Annexure 1
Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities
Introduced 01/08/12 Amended 04/03/13
Part 1
|
|
|
Rule 7.1 Issues exceeding 15% of capital
|
|
Step 1: Calculate
A, the base figure from which the placement capacity is calculated
|
|
|
Insert
number of fully paid +ordinary securities on issue 12 months before the
+issue date or date of agreement to issue
|
|
103,805,676
|
|
|
Add
the following:
Number of fully paid
+ordinary securities issued in that 12 month period under an exception in rule 7.2
Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval
Number of partly paid +ordinary securities that became fully paid in that 12 month
period
Note:
Include only
ordinary securities here other classes of equity securities cannot be added
Include here (if applicable) the securities the subject of the Appendix 3B to which
this form is annexed
It may be useful to set out issues of securities on different dates as separate line
items
|
|
34,470,357
|
|
|
Subtract
the number of fully paid +ordinary securities cancelled during that
12 month period
|
|
|
|
|
A
|
|
138,276,033
|
+
|
See chapter 19 for defined terms.
|
|
|
|
24/10/2005 Appendix 3B Page 11
|
|
|
Appendix 3B
New issue announcement
|
|
|
Step 2: Calculate 15% of A
|
|
|
B
|
|
|
|
|
Multiply
A by 0.15
|
|
20,741,404
|
|
Step 3: Calculate
C, the amount of placement capacity under rule 7.1 that has already been used
|
|
|
Insert
number of +equity
securities issued or agreed to be issued in that 12 month period
not counting
those issued:
Under an exception in rule 7.2
Under rule
7.1A
With
security holder approval under rule 7.1 or rule 7.4
Note:
This applies to equity securities, unless specifically excluded not just
ordinary securities
Include here (if applicable) the securities the subject of the Appendix 3B to which
this form is annexed
It may be useful to set out issues of securities on different dates as separate line
items
|
|
4,822,369
|
|
|
C
|
|
4,822,369
|
|
Step 4: Subtract
C from [A x B] to calculate remaining placement capacity under rule 7.1
|
|
|
A x 0.15
Note: number must be same as shown in Step 2
|
|
20,741,404
|
|
|
Subtract
C
Note: number must be same as shown in Step 3
|
|
4,822,369
|
|
|
Total
[A x 0.15] C
|
|
15,909,035
|
+
|
See chapter 19 for defined terms.
|
|
|
|
Appendix 3B Page 12
|
|
1/1/2003
|
Appendix 3B
New issue announcement
Part 2
|
|
|
Rule 7.1A Additional placement capacity for eligible
entities
|
|
Step 1: Calculate
A, the base figure from which the placement capacity is calculated
|
|
|
A
Note: number must be same as shown in Step 1 of Part 1
|
|
N/A
|
|
Step 2: Calculate 10%
of A
|
|
|
D
|
|
N/A
|
|
|
Multiply
A by 0.10
|
|
N/A
|
|
Step 3: Calculate
E, the amount of placement capacity under rule 7.1A that has already been used
|
|
|
Insert
number of +equity
securities issued or agreed to be issued in that 12 month period under rule 7.1A
Notes:
This applies to equity securities not just ordinary securities
Include here if applicable the securities the subject of the Appendix 3B
to which this form is annexed
Do not include equity securities issued under rule 7.1 (they must be dealt with in
Part 1), or for which specific security holder approval has been obtained
It may be useful to set out issues of securities on different dates as separate line items
|
|
N/A
|
|
|
E
|
|
N/A
|
+
|
See chapter 19 for defined terms.
|
|
|
|
24/10/2005 Appendix 3B Page 13
|
|
|
Appendix 3B
New issue announcement
|
|
|
Step 4: Subtract E from [A x D] to calculate remaining
placement capacity under rule 7.1A
|
|
|
A x 0.10
Note: number must be same as shown in Step 2
|
|
N/A
|
|
|
Subtract
E
Note: number must be same as shown in Step 3
|
|
N/A
|
|
|
Total
[A x 0.10] E
|
|
Note: this is the remaining placement capacity under
rule 7.1A
|
+
|
See chapter 19 for defined terms.
|
|
|
|
Appendix 3B Page 14
|
|
1/1/2003
|
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Oct 2023 to Oct 2024